Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Jan Hrabeta"'
Autor:
Radka Hobzova, Jakub Sirc, Kusum Shrestha, Barbora Mudrova, Zuzana Bosakova, Miroslav Slouf, Marcela Munzarova, Jan Hrabeta, Tereza Feglarova, Ana-Irina Cocarta
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1398 (2023)
Local chemotherapy using polymer drug delivery systems has the potential to treat some cancers, including intraocular retinoblastoma, which is difficult to treat with systemically delivered drugs. Well-designed carriers can provide the required drug
Externí odkaz:
https://doaj.org/article/dc055db59e3d4d1d96a4cddc19945925
Autor:
Katerina Kopeckova, Tomas Eckschlager, Jakub Sirc, Radka Hobzova, Johana Plch, Jan Hrabeta, Jiri Michalek
Publikováno v:
Biomedical Papers, Vol 163, Iss 2, Pp 122-131 (2019)
Cancer despite the introduction of new targeted therapy remains for many patients a fatal disease. Nanotechnology in cancer medicine has emerged as a promising approach to defeat cancer. Targeted delivery of anti-cancer drugs by different nanosystems
Externí odkaz:
https://doaj.org/article/12a95c3a29c2432da570dc4f529a1450
Publikováno v:
Biomedical Papers, Vol 159, Iss 2, Pp 166-177 (2015)
Background: The aim of this review is to provide the information about molecular basis of hypoxia-induced chemoresistance, focusing on the possibility of diagnostic and therapeutic use. Results: Hypoxia is a common feature of tumors and represents an
Externí odkaz:
https://doaj.org/article/9753e35b8886484eb8453acea3e74463
Autor:
Martina Raudenska, Ludmila Krejcova, Lukas Richtera, Zbynek Heger, Jan Hrabeta, Tomas Eckschlager, Marie Stiborova, Vojtech Adam, Monika Kratochvilova, Michal Masarik, Jaromir Gumulec
Publikováno v:
Tumor Biology, Vol 39 (2017)
Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valpr
Externí odkaz:
https://doaj.org/article/b0971fb99a644becbfca7f7df620ebb9
Autor:
Martina Kodetova, Karel Svojgr, Radka Hobzova, Jakub Sirc, Jan Hrabeta, Barbara Feriancikova, Daniela Kodetova, Jiri Uhlik, Ana-Irina Cocarta, Kusum Shrestha, Taras Ardan, Yaroslav Nemesh, Jan Motlik, Jana Cizkova, Jana Juhasova, Stefan Juhas, Zbynek Stranak, Pavel Pochop
Publikováno v:
SSRN Electronic Journal.
Autor:
Simona Dostalova, Tereza Cerna, David Hynek, Zuzana Koudelkova, Tomas Vaculovic, Pavel Kopel, Jan Hrabeta, Zbynek Heger, Marketa Vaculovicova, Tomas Eckschlager, Marie Stiborova, Vojtech Adam
Publikováno v:
ACS Applied Materials & Interfaces. 14:31510-31511
Autor:
Jindrich Cinatl, Jr., Martin Michaelis, Pablo Hernáiz Drievert, Jaroslav Cinatl, Jan Hrabeta, Tatyana Suhan, Hans Wilhelm Doerr, Jens-Uwe Vogel
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 6, Iss 6, Pp 725-735 (2004)
The mode of the antitumoral activity of multimutated oncolytic herpes simplex virus type 1 G207 has not been fully elucidated yet. Because the antitumoral activity of many drugs involves the inhibition of tumor blood vessel formation, we determined i
Externí odkaz:
https://doaj.org/article/eac74f060b44471a87414303bafc4789
Autor:
Johana Plch, Jakub Sirc, Tomas Eckschlager, Katerina Kopeckova, Radka Hobzova, Jan Hrabeta, Jiri Michalek
Publikováno v:
Biomedical Papers, Vol 163, Iss 2, Pp 122-131 (2019)
Cancer despite the introduction of new targeted therapy remains for many patients a fatal disease. Nanotechnology in cancer medicine has emerged as a promising approach to defeat cancer. Targeted delivery of anti-cancer drugs by different nanosystems
Autor:
Tomas Kalina, Petr Liby, Daniela Kuzilkova, Josef Zamecnik, Ales Vicha, Jan Stary, Michal Tichy, Martina Vaskova, Jan Hrabeta, Ondrej Hrusak
Publikováno v:
Journal of Neuro-Oncology. 143:15-25
The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. CUSA specimens obtained from 19 pediatric patients w
Autor:
Hana Buchtelova, J I Casal, Vivian de los Ríos, Marie Belhajová, Tomas Eckschlager, Jan Hrabeta, Miguel Angel Merlos Rodrigo, Zbynek Heger, Vojtech Adam
Publikováno v:
Journal of Proteome Research
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL OF PROTEOME RESEARCH. 2019, vol. 18, issue 3, p. 1255-1263.
Digital.CSIC. Repositorio Institucional del CSIC
instname
JOURNAL OF PROTEOME RESEARCH. 2019, vol. 18, issue 3, p. 1255-1263.
28 p.-6 fig.
Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying the develop
Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying the develop